Literature DB >> 8822972

Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein.

K D O'Brien1, C E Alpers, J E Hokanson, S Wang, A Chait.   

Abstract

BACKGROUND: Previous small studies have demonstrated positive immunohistochemical staining in rabbit and human atherosclerotic plaques by antibodies that recognize oxidized low-density lipoprotein (OxLDL), but none have examined a large number of human coronary arteries or evaluated whether epitopes recognized by these antibodies might be present on plaque proteins other than OxLDL. METHODS AND
RESULTS: Immunohistochemistry was performed on atherosclerotic (n = 87) and nonatherosclerotic (n = 51) coronary arterial segments from 20 patients by use of monoclonal antibodies that recognize epitopes on macrophages, smooth muscle cells, apolipoprotein (apo) B, and OxLDL. Staining with the OxLDL antibody (Ox5) was much more prevalent in atherosclerotic than in control segments. Extracellular Ox5 staining colocalized with apo B, but cell-associated Ox5 staining occurred in the absence of cell-associated apo B staining, which suggests that cell-associated epitopes for Ox5 were on proteins other than LDL. Epitopes for Ox5 formed in vitro on two readily available non-apo B proteins, human serum albumin and apo A-I, when these proteins were incubated under conditions of oxidant stress with polyunsaturated but not monounsaturated fatty acids; furthermore, an antioxidant inhibited Ox5 epitope formation. Thus, epitopes for Ox5 can form on proteins other than apo B. Also, phorbol ester-treated macrophages cultured in apo B-free medium developed epitopes for Ox5.
CONCLUSIONS: These findings are consistent with the hypothesis that atherosclerosis is associated with oxidative modification of proteins in addition to LDL, particularly cell-associated proteins, and that the antiatherosclerotic effects of antioxidants seen in some studies may not be solely due to prevention of LDL oxidation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8822972     DOI: 10.1161/01.cir.94.6.1216

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Relation between plasma oxLDL antibodies and oxLDL in the circulation.

Authors:  Yan Wang; Xueqiang Fang; Shumei Wang; Yueqiu Feng; Jinghai Yin
Journal:  Inflammation       Date:  2006-12-02       Impact factor: 4.092

2.  Cholesterol-induced membrane microvesicles as novel carriers of damage-associated molecular patterns: mechanisms of formation, action, and detoxification.

Authors:  Ming-Lin Liu; Rosario Scalia; Jawahar L Mehta; Kevin Jon Williams
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-07-19       Impact factor: 8.311

3.  Coronary heart disease: Significance of liver X receptor α genomics.

Authors:  Vivek Priy Dave; Deepak Kaul
Journal:  World J Cardiol       Date:  2010-06-26

Review 4.  Current, new and future treatments in dyslipidaemia and atherosclerosis.

Authors:  P H Chong; B S Bachenheimer
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

5.  Plasma glycosylphosphatidylinositol-specific phospholipase D predicts the change in insulin sensitivity in response to a low-fat but not a low-carbohydrate diet in obese women.

Authors:  Dona L Gray; Kevin D O'Brien; David A D'Alessio; Bonnie J Brehm; Mark A Deeg
Journal:  Metabolism       Date:  2008-04       Impact factor: 8.694

Review 6.  NADPH Oxidase Deficiency: A Multisystem Approach.

Authors:  Giuliana Giardino; Maria Pia Cicalese; Ottavia Delmonte; Maddalena Migliavacca; Boaz Palterer; Lorenzo Loffredo; Emilia Cirillo; Vera Gallo; Francesco Violi; Claudio Pignata
Journal:  Oxid Med Cell Longev       Date:  2017-12-21       Impact factor: 6.543

Review 7.  Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies.

Authors:  Cédric Delporte; Pierre Van Antwerpen; Luc Vanhamme; Thierry Roumeguère; Karim Zouaoui Boudjeltia
Journal:  Mediators Inflamm       Date:  2013-07-24       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.